Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04742959 · ClinicalTrials.gov registry record · Phase 1
Study of TT-00420 (Tinengotinib) Tablet as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors
A Phase 1 study, sponsored by TransThera Sciences (Nanjing).
- Completed
- Registry status
- Phase 1
- Development phase
- 203
- Enrollment target
NCT04742959 is a Phase 1 study that has completed, run by TransThera Sciences (Nanjing). The registered enrollment target is 203 participants.
The verdict
NCT04742959, a Phase 1 study, has completed, sponsored by TransThera Sciences (Nanjing).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 203 participants
- Enrollment target
Study Summary
This is a Phase Ib/II, multicenter, open-label study to evaluate the safety and preliminary efficacy of TT-00420 tablet, as monotherapy or in combination regimens, in patients with advanced solid tumors.
Interventions
- DRUG TT-00420
- COMBINATION_PRODUCT Nab-Paclitaxel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 203 participants |
| Start Date | 2021-03-14 |
| Est. Completion | 2024-02-20 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04742959
The ClinicalTrials.gov registry entry for NCT04742959 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 203 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is TransThera Sciences (Nanjing), which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which TT-00420 is the first listed.
NCT04742959 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04742959 about?
NCT04742959 is a clinical study titled "Study of TT-00420 (Tinengotinib) Tablet as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors". This is a Phase Ib/II, multicenter, open-label study to evaluate the safety and preliminary efficacy of TT-00420 tablet, as monotherapy or in combination regimens, in patients with advanced solid tumors.
What is the current status of trial NCT04742959?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 203 participants. The study started on 2021-03-14. Estimated completion is 2024-02-20.
What interventions are being tested in trial NCT04742959?
The interventions under investigation include: TT-00420 (DRUG), Nab-Paclitaxel (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT04742959?
This trial is sponsored by TransThera Sciences (Nanjing), which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.